Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices

SIGNIFICANCE AND USE
4.1 The objective of this guide is to recommend a panel of biological tests that can be used in addition to the testing recommended in Practice F748. This guide is designed to detect neurotoxicity caused by medical devices that contact nervous tissue.  
4.2 The testing recommendations should be considered for new materials, established materials with different manufacturing methods that could affect nervous tissue response, or materials used in new nervous tissue applications.  
4.3 Chemical characterization can be used to evaluate similarity for materials with a history of clinical use in a similar nervous tissue application.
SCOPE
1.1 Medical devices may cause adverse effects on the structure and/or function of the nervous system. In this guide, these adverse effects are defined as neurotoxicity. This guide provides background information and recommendations on methods for neurotoxicity testing. This guide should be used with Practice F748, and may be helpful where neurotoxicity testing is needed to evaluate medical devices that contact central and/or peripheral nervous system tissue or cerebral spinal fluid (CSF).
Note 1: The results of these in vitro and in vivo tests may not correspond to actual human response.  
1.2 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety, health, and environmental practices and determine the applicability of regulatory limitations prior to use.  
1.3 This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.

General Information

Status
Published
Publication Date
28-Feb-2019
Current Stage
Ref Project

Relations

Buy Standard

Guide
ASTM F2901-19 - Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices
English language
5 pages
sale 15% off
Preview
sale 15% off
Preview
Guide
REDLINE ASTM F2901-19 - Standard Guide for Selecting Tests to Evaluate Potential Neurotoxicity of Medical Devices
English language
5 pages
sale 15% off
Preview
sale 15% off
Preview

Standards Content (Sample)

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the
Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
Designation: F2901 − 19
Standard Guide for
Selecting Tests to Evaluate Potential Neurotoxicity of
1
Medical Devices
This standard is issued under the fixed designation F2901; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope 2.2 Other Referenced Documents:
ISO 10993-1 Biological Evaluation of Medical Devices—
1.1 Medical devices may cause adverse effects on the
Part 1: Evaluation andTestingWithin a Risk Management
structure and/or function of the nervous system. In this guide,
Process
these adverse effects are defined as neurotoxicity. This guide
ISO 10993-3 Biological Evaluation of Medical Devices—
provides background information and recommendations on
Part 3: Tests for Genotoxicity, Carcinogenicity, and Re-
methods for neurotoxicity testing. This guide should be used
3
productive Toxicity
with Practice F748, and may be helpful where neurotoxicity
ISO 10993-5 Biological Evaluation of Medical Devices—
testing is needed to evaluate medical devices that contact
3
Part 5: Tests for In Vitro Cytotoxicity
central and/or peripheral nervous system tissue or cerebral
ISO 10993-6 Biological Evaluation of Medical Devices—
spinal fluid (CSF).
Part 6: Tests for Local Effects After Implantation
NOTE 1—The results of these in vitro and in vivo tests may not
correspond to actual human response.
ISO 10993–11 Biological Evaluation of Medical Devices—
Part 11: Tests for Systemic Toxicity
1.2 This standard does not purport to address all of the
safety concerns, if any, associated with its use. It is the ISO 10993-18 Biological Evaluation of Medical Devices—
3
responsibility of the user of this standard to establish appro- Part 18: Chemical Characterization of Materials
priate safety, health, and environmental practices and deter- ANSI/AAMI ST72 Bacterial Endotoxins—Test
mine the applicability of regulatory limitations prior to use. Methodologies, Routine Monitoring, and Alternatives to
3
1.3 This international standard was developed in accor-
Batch Testing
4
dance with internationally recognized principles on standard- USP <151> Rabbit Pyrogen Test
ization established in the Decision on Principles for the
USP <161> Transfusion and Infusion Assemblies and Simi-
4
Development of International Standards, Guides and Recom-
lar Medical Devices
mendations issued by the World Trade Organization Technical
Barriers to Trade (TBT) Committee.
3. Summary of Guide
3.1 This is an informative guide and should be used with
2. Referenced Documents
Practice F748.
2
2.1 ASTM Standards:
3.2 The duration of contact between the tissue and medical
F748 PracticeforSelectingGenericBiologicalTestMethods
device should be considered when determining the appropriate
for Materials and Devices
F756 Practice for Assessment of Hemolytic Properties of panel of testing. This guide may not address neurosurgical
instruments or medical devices that have transient incidental
Materials
F1904 Practice for Testing the Biological Responses to contact with the nervous system due to the limited tissue
Particles in vivo contact duration.
3.3 The evaluation of neurotoxicity should be considered in
conjunction with material characterization and other informa-
1
This guide is under the jurisdiction of ASTM Committee F04 on Medical and
tion such as non-clinical tests, clinical studies, post-market
Surgical Materials and Devices and is the direct responsibility of Subcommittee
experience, and intended use.
F04.16 on Biocompatibility Test Methods.
Current edition approved March 1, 2019. Published March 2019. Originally
approved in 2012. Last previous edition approved in 2013 as F2901 – 13. DOI:
10.1520/F2901–19.
2 3
For referenced ASTM standards, visit the ASTM website, www.astm.org, or Available fromAmerican National Standards Institute (ANSI), 25 W. 43rd St.,
contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM 4th Floor, New York, NY 10036, http://www.ansi.org.
4
Standards volume information, refer to the standard’s Document Summary page on Available from U.S. Pharmacopeia (USP), 12601Twinbrook Pkwy., Rockville,
the ASTM website. MD 20852-1790, http://www.usp.org.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----------------------
F2901 − 19
4. Significance and Use in-vitro test with cytogenetic evaluation of chromosomal
damage with mammalian cells or an in-vitro mouse lymphoma
4
...

This document is not an ASTM standard and is intended only to provide the user of an ASTM standard an indication of what changes have been made to the previous version. Because
it may not be technically possible to adequately depict all changes accurately, ASTM recommends that users consult prior editions as appropriate. In all cases only the current version
of the standard as published by ASTM is to be considered the official document.
Designation: F2901 − 13 F2901 − 19
Standard Guide for
Selecting Tests to Evaluate Potential Neurotoxicity of
1
Medical Devices
This standard is issued under the fixed designation F2901; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope
1.1 Medical devices may cause adverse effects on the structure and/or function of the nervous system. In this guide, these
adverse effects are defined as neurotoxicity. This guide provides background information and recommendations on methods for
neurotoxicity testing. This guide should be used with Practice F748, and may be helpful where neurotoxicity testing is needed to
evaluate medical devices that contact central and/or peripheral nervous system tissue or cerebral spinal fluid (CSF).
NOTE 1—The results of these in vitro and in vivo tests may not correspond to actual human response.
1.2 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility
of the user of this standard to establish appropriate safety safety, health, and healthenvironmental practices and determine the
applicability of regulatory limitations prior to use.
1.3 This international standard was developed in accordance with internationally recognized principles on standardization
established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued
by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
2. Referenced Documents
2
2.1 ASTM Standards:
F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices
F756 Practice for Assessment of Hemolytic Properties of Materials
F1904 Practice for Testing the Biological Responses to Particles in vivo
2.2 Other Referenced Documents:
ISO 10993-1 Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing Within a Risk Management Process
ISO/AAMI/ANSIISO 10993-3 :2003 Biological Evaluation of Medical Devices—Part 3: Tests for Genotoxicity,
3
Carcinogenicity, and Reproductive Toxicity
3
ISO/AAMI/ANSIISO 10993-5 :2009 Biological Evaluation of Medical Devices—Part 5: Tests for In Vitro Cytotoxicity
ISO 10993-6 Biological Evaluation of Medical Devices—Part 6: Tests for Local Effects After Implantation
ISO 10993–11 : 2006 Biological Evaluation of Medical Devices—Part 11: Tests for Systemic Toxicity
3
ISO/AAMI/ANSIISO 10993-18 Biological Evaluation of Medical Devices—Part 18: Chemical Characterization of Materials
ANSI/AAMI ST72ANSI/AAMI ST72 :2010 Bacterial Endotoxins—Test Bacterial Endotoxins—Test Methodologies, Routine
3
Monitoring, and Alternatives to Batch Testing
4
USP <151> Rabbit Pyrogen Test
4
USP <161> Transfusion and Infusion Assemblies and Similar Medical Devices
3. Summary of Guide
3.1 This is an informative guide and should be used with Practice F748.
1
This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.16
on Biocompatibility Test Methods.
Current edition approved Feb. 1, 2013March 1, 2019. Published February 2013March 2019. Originally approved in 2012. Last previous edition approved in 20122013
as F2901 – 12.F2901 – 13. DOI: 10.1520/F2901–13. 10.1520/F2901–19.
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM Standards
volume information, refer to the standard’s Document Summary page on the ASTM website.
3
Available from American National Standards Institute (ANSI), 25 W. 43rd St., 4th Floor, New York, NY 10036, http://www.ansi.org.
4
Available from U.S. Pharmacopeia (USP), 12601 Twinbrook Pkwy., Rockville, MD 20852-1790, http://www.usp.org.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----------------------
F2901 − 19
3.2 The duration of contact between the tissue and medical device should be considered when determining the appropriate panel
of testing. This guide may not address neurosurgical instruments or medical devices that have transient incidental contact with the
nervous system due to the limited tissue contact duration.
3.3 The evaluation of neurotoxicity should be considered
...

Questions, Comments and Discussion

Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.